Assertio (ASRT) CEO exits all shares and awards in $23.50-per-share cash merger
Rhea-AI Filing Summary
Assertio Holdings, Inc. CEO Mark L. Reisenauer reported the disposition of all his reported equity interests in connection with Assertio’s cash merger with an affiliate of Zydus. A tender offer acquired all outstanding Assertio common shares at $23.50 per share in cash, after which the merger closed.
The filing shows 3,583 common shares cancelled and converted into the right to receive cash. In addition, 33,333 restricted stock units became fully vested immediately before the merger and were then cancelled for a cash payment per unit equal to the $23.50 offer price.
Stock options with exercise prices below the offer price, including 26,667 options at $11.77, 66,666 options at $12.372, and 5,415 options at $12.7515, were cancelled and converted into cash equal to the spread between $23.50 and the respective exercise prices, multiplied by the optioned shares. Options with exercise prices at or above $23.50 were cancelled without payment. Following these transactions, the Form 4 reports zero common shares, stock options, or RSUs remaining for the CEO.
Positive
- None.
Negative
- None.
Insights
CEO’s equity is cashed out in a completed cash merger.
This Form 4 reflects mechanical clean-up of equity awards as Assertio is acquired for cash at $23.50 per share. The CEO’s common shares, in-the-money options, and RSUs are all cancelled and converted into cash rights under the merger agreement.
The transactions use codes U and D, indicating a tender-offer-related disposition and returns to the issuer, not open-market buying or selling. Afterward, the filing shows zero remaining equity or derivatives, consistent with Assertio becoming a wholly owned subsidiary. The market impact comes from the merger itself; this Form 4 mainly documents how executive equity was settled.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Restricted Stock Units | 33,333 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 5,415 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 66,666 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 26,667 | $0.00 | -- |
| U | Common Stock | 3,583 | $0.00 | -- |
Footnotes (1)
- On December 26, 2025, the Issuer effected a 1-for-15 reverse stock split (the "Reverse Stock Split"). The number of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 13, 2026, by and among Assertio Holdings, Inc. (the "Issuer"), Zydus Worldwide DMCC ("Parent"), Zara Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser") and Zydus Pharmaceuticals (USA) Inc., pursuant to which Purchaser completed a tender offer (the "Offer") for all outstanding shares of common stock of the Issuer ("Company Common Stock") at a price of $23.50 per share in cash, without interest (the "Offer Price"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"), effective as of June 16, 2026 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right [continues to Footnote 3] [continues from Footnote 2] to receive the Offer Price, less any applicable withholding taxes. Pursuant to the Merger Agreement, each restricted stock unit of the Issuer (each, a "Company RSU") that was outstanding but unvested immediately prior to the Effective Time became fully vested as of immediately prior to the Effective Time and, at the Effective Time, each outstanding Company RSU was cancelled and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the Offer Price. Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock (each, a "Company Stock Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, with an exercise price per share less than the Offer Price, was cancelled at the Effective Time and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the product of (A) the excess of the Offer Price over the exercise price payable per share of Company Common Stock under such Company Stock Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Stock Option. Each Company Stock Option with an exercise price per share equal to or greater than the Offer Price was cancelled at the Effective Time without any cash payment in respect thereof.